

A Brief Report on Alumni Interaction Series 2023 – Lecture 14
(Bridging the gap - Connecting to the World)

Name of the presenter:

Mr Abraham Jacob
APAC Regulatory Affairs Oncology Lead,
Menarini Asia-Pacific,
Singapore.



Title of the presentation: "Current trends and reflections in Oncology Drug Development"

Date of the Presentation: 18.12.2023

Program Organized by: Dept. of Pharmacy Practice & Pharmacy Education Unit, JSS College of Pharmacy, Ooty.

As a part of the Alumni interactions 2023, the series was held on 18.12.2023 by one of the proud Alumnus of Department of Pharmacy Practice, Mr Abraham Jacob, APAC Regulatory Affairs Oncology Lead, Menarini Asia-Pacific, Singapore.

Mr Abraham Jacob, got his basic education from Oman and completed his Bachelor of Pharmacy in JSS College of Pharmacy, Ooty and started his career as a Marketing Liaison in Sanofi Aventis. He completed his Master of Pharmacy in Manipal College of Pharmacy and got posted in Regulatory affairs in Getwell Pharma and worked in Novartis for 13 years. He also pursued his Master of Science in RAHP and currently he is working in APAC Regulatory Affairs Oncology Lead, Menarini Asia-Pacific, Singapore.

Mr Abraham Jacob, a renowned expert in the field of Regulatory Affairs and Clinical Research conducted an informative session in JSS College of Pharmacy, Ooty on 18.12.2023. The session aimed to guide participants on drug development process on oncology. Mr. Abraham provided a comprehensive overview of the current landscape in oncology drug development, outlining the key factors that drive research and innovation in this field. The speaker highlighted several emerging trends influencing the development of oncology drugs, such as precision medicine, the changes in Clinical Trials including decentralized clinical trials, adaptive clinical trial designs, diversity in clinical trials. He also discussed about changes in Regulations & Health Policy including regulatory convergence, real world evidence, evolution of regulatory submissions, ACCESS and paying for benefit and the latest buzz like the Nitrosamine story, e-labelling, personalized medicine. Mr Abraham described the global pharmaceutical market and displayed the predicted oncology market for 2022 to 2032.

Attendees gained valuable insights into recent innovations and breakthroughs in oncology drug development, including novel therapeutic approaches and successful clinical trials. Mr. Abraham discussed the challenges faced by researchers and pharmaceutical companies in the oncology sector, emphasizing the need for collaboration and novel solutions. He also highlighted the opportunities for advancements in personalized medicine.

Mr Abraham Jacob then concluded her presentation followed by taking up queries from the audience and staff, Department of Pharmacy Practice. Around 90 participants fruitfully benefited through this Alumni Interaction Series.

